OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Acquisition extends ICON’s presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease
Dublin, Ireland – ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the previously announced acquisition of Clinical Research Management, Inc. (ClinicalRM). ClinicalRM provides full service and functional research solutions to a broad range of U.S. government agencies. Their extensive expertise extends across basic and applied research, infectious diseases, vaccine development and testing and response to bio-threats. In addition, they have worked in collaboration with government and commercial customers to respond to the threat of global viral epidemics. Commenting on the acquisition, ICON’s Chief Executive Officer, Ciaran Murray said: “ClinicalRM has a strong track record of partnering successfully with government agencies and NGOs. They will provide a platform for ICON to further penetrate this significant market segment as we continue to grow and diversify our customer base. ClinicalRM’s work in the area of global vaccine development will further enhance our capabilities in this important area to the benefit of customers and patients globally.”
ClinicalRM is a full-service Contract Research Organization specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs and devices. The organization helps customers get their products to market faster with a wide array of research, regulatory and sponsor services within the U.S. and around the globe. From international partnerships and affiliations to government relations and local alliances, ClinicalRM delivers a synergy in the global market with projects spanning the government, academic and commercial marketplaces. ClinicalRM has a distinct ability to provide boots-on-the-ground and rapid response efforts to global health crises. More information is at
About ICON plc
ICON plc is a global provider of drug development solutions and
to the pharmaceutical, biotechnology and medical device industries. ICON specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 89 locations in 37 countries and has approximately 12,300 employees. Further information is available at